Who are Rosuvastatin-pantoprazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atorvastatin-esomeprazole, Rosuvastatin-omeprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosuvastatin-pantoprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rosuvastatin-pantoprazole — Competitive Intelligence Brief

Rosuvastatin-pantoprazole (Rosuvastatin-pantoprazole) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin + proton pump inhibitor combination. Area: Cardiovascular.

marketed Statin + proton pump inhibitor combination HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rosuvastatin-pantoprazole (Rosuvastatin-pantoprazole) — Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rosuvastatin-pantoprazole TARGET	Rosuvastatin-pantoprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (pantoprazole)
Atorvastatin-esomeprazole	Atorvastatin-esomeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase; H+/K+-ATPase
Rosuvastatin-omeprazole	Rosuvastatin-omeprazole	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Statin + proton pump inhibitor combination	HMG-CoA reductase (rosuvastatin); H+/K+-ATPase (omeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin + proton pump inhibitor combination class)

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosuvastatin-pantoprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-pantoprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab